Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Marco Valgimigli , Diana Gorog , Eliano Navarese , et al Added: 1 year ago
This on-demand version of the live roundtable, chaired by Prof Marco Valgimigli (Cardiocentro Ticino Institute, Lugano, CH), demonstrates how to prioritise bleeding and ischaemic risks in coronary arterial disease (CAD) management. Key opinion leaders Prof Diana Gorog (University of Hertfordshire, UK), Prof Felicita Andreotti (Gemelli University Hospital, Rome, IT) and Prof Eliano Navarese … View more
Author(s): William Herrington Added: 6 months ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an… View more
Author(s): Paul M Ridker Added: 1 year ago
ACC.23/WCC - We are joined by Dr Paul Ridker (Brigham and Women’s Hospital, US) to discuss the findings from a collaborative analysis of 31,197 patients to assess inflammatory risk in statin-treated patients. The PROMINENT, REDUCE-IT and STRENGTH trials were each large contemporary trials which implemented guideline-directed medical therapy, the findings of which were pooled in this study. The… View more
Author(s): Niklas Dyrby Johansen Added: 1 year ago
ESC-HFA 23 – We are joined onsite by Dr Niklas Dyrby Johansen (Herlev and Gentofte Hospital, DK) to discuss the late-breaking results of the NUDGE-FLU trial in a cohort of patients with cardiovascular disease (CVD) (NCT05542004). NUDGE-FLU is a prospective, randomized, open-label implementation trial that enrolled over 96,0000 patients across Denmark. The study population included individuals… View more
Author(s): Samuel S Engel Added: 1 year ago
EASD 2023 — In this short interview, Dr Samuel S Engel (Associate Vice President at Merck) discusses a study investigating the effectiveness and safety of efinopegdutide (MK-6024) in patients with nonalcoholic fatty liver disease and type 2 diabetes (NCT04944992).The phase IIa study randomized 145 participants (efinopegdutide, n = 72; semaglutide, n = 73). The majority (55.2%) of participants… View more
Author(s): Lee Kaplan , Fatima Cody Stanford , Filip Knop , et al Added: 1 year ago
Radcliffe Medical Education bring together a distinguished panel of globally renowned experts who provide guidance on navigating the ever-changing landscape of obesity and metabolic health management. Under the chairmanship of Prof Jason Halford(University of Leeds, UK), the panel includingDr Lee Kaplan(Obesity, Metabolism and Nutrition Institute, Massachusetts General Hospital, US),Dr… View more
Author(s): William T Abraham , Hanad Bashir Added: 1 year ago
AHA 23 — Dr Hanad Bashir, CardioNerds ambassador, interviews Prof William T Abraham (The Ohio State University, US) on the findings of a clinical evaluation of the Cordio app in adult patients with acute decompensated heart failure.The Cordio "HearO" app (Cordio Medical) uses patient speech sampled via mobile phone to sense fluid accumulation related to chronic heart failure, and provides alerts… View more